Exact Mass: 345.07863380000003

Exact Mass Matches: 345.07863380000003

Found 271 metabolites which its exact mass value is equals to given mass value 345.07863380000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

NITRALIN

C13H19N3O6S (345.0994514)

Triflumizole

Pesticide6_Triflumizole_C15H15ClF3N3O_4-Chloro-N-[(1E)-1-(1H-imidazol-1-yl)-2-propoxyethylidene]-2-(trifluoromethyl)benzenamine

C15H15ClF3N3O (345.0855686)

CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4745; ORIGINAL_PRECURSOR_SCAN_NO 4742 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4719; ORIGINAL_PRECURSOR_SCAN_NO 4717 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4736; ORIGINAL_PRECURSOR_SCAN_NO 4734 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4793; ORIGINAL_PRECURSOR_SCAN_NO 4791 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4768; ORIGINAL_PRECURSOR_SCAN_NO 4766 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4866; ORIGINAL_PRECURSOR_SCAN_NO 4864 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9932; ORIGINAL_PRECURSOR_SCAN_NO 9930 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9966; ORIGINAL_PRECURSOR_SCAN_NO 9964 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9898; ORIGINAL_PRECURSOR_SCAN_NO 9896 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9932; ORIGINAL_PRECURSOR_SCAN_NO 9927 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9953; ORIGINAL_PRECURSOR_SCAN_NO 9952 CONFIDENCE standard compound; INTERNAL_ID 1088; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9950; ORIGINAL_PRECURSOR_SCAN_NO 9949

Azinphos-ethyl

O,O-diethyl {[(4-oxo-3,4-dihydro-1,2,3-benzotriazin-3-yl)methyl]sulfanyl}phosphonothioate

C12H16N3O3PS2 (345.0370676)

C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor CONFIDENCE standard compound; EAWAG_UCHEM_ID 3654 CONFIDENCE standard compound; INTERNAL_ID 2608 CONFIDENCE standard compound; INTERNAL_ID 8478

Omeprazole

6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-methyl-1H-benzo[d]imidazole

C17H19N3O3S (345.11470640000005)

Omeprazole is a highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers, dyspepsia, peptic ulcer disease , gastroesophageal reflux disease and Zollinger-Ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of Gastric Parietal Cells.--Pubchem. Omeprazole is one of the most widely prescribed drugs internationally and is available over the counter in some countries. Proton pump inhibitor, inhibits gastric acid secretion. Antiulcer agent. It is used in combination with Amoxicillin for eradication of Helicobacter pylori and for the treatment of gastroesophageal reflux disease (CCD) A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

Cyclic GMP

9-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-hexahydro-2λ⁵-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-amino-6,9-dihydro-1H-purin-6-one

C10H12N5O7P (345.0474332)

Cyclic-gmp, also known as cgmp or guanosine 3,5-cyclic monophosphate, is a member of the class of compounds known as 3,5-cyclic purine nucleotides. 3,5-cyclic purine nucleotides are purine nucleotides in which the oxygen atoms linked to the C3 and C5 carbon atoms of the ribose moiety are both bonded the same phosphorus atom of the phosphate group. Cyclic-gmp is slightly soluble (in water) and a moderately acidic compound (based on its pKa). Cyclic-gmp can be found in a number of food items such as common sage, jews ear, java plum, and pepper (c. chinense), which makes cyclic-gmp a potential biomarker for the consumption of these food products. Cyclic-gmp can be found primarily in blood and cerebrospinal fluid (CSF), as well as throughout most human tissues. Cyclic-gmp exists in all living species, ranging from bacteria to humans. Moreover, cyclic-gmp is found to be associated with headache. Guanosine cyclic 3,5-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3- and 5-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). Acquisition and generation of the data is financially supported in part by CREST/JST. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Thiamine monophosphate

2-[3-[(4-Azanyl-2-methyl-pyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl dihydrogen phosphoric acid

[C12H18N4O4PS]+ (345.07863380000003)

Thiamine monophosphate, also known as thiamin phosphoric acid or TMP, belongs to the class of organic compounds known as thiamine phosphates. These are thiamine derivatives in which the hydroxyl group of the ethanol moiety is substituted by a phosphate group. Thiamine monophosphate is a very strong basic compound (based on its pKa). Thiamine monophosphate is one of the five known natural thiamine phosphate derivatives. Thiamine (vitamin B1) is the transport form of the vitamin while the phosphorylated derivatives are the active forms. Thiamine dihydrogen phosphate ester. The monophosphate ester of thiamine. Synonyms: monophosphothiamine; vitamin B1 monophosphate. -- Pubchem [HMDB] Acquisition and generation of the data is financially supported in part by CREST/JST. D018977 - Micronutrients > D014815 - Vitamins KEIO_ID T057; [MS3] KO009298 KEIO_ID T057; [MS2] KO009297 KEIO_ID T057

Guanosine 2',3'-cyclic phosphate

9-[(3aR,4R,6R,6aR)-2-hydroxy-6-(hydroxymethyl)-2-oxo-tetrahydro-2H-2λ⁵-furo[3,4-d][1,3,2]dioxaphosphol-4-yl]-2-amino-6,9-dihydro-3H-purin-6-one

C10H12N5O7P (345.0474332)

2,3-Cyclic GMP is a cyclic guanosine derivative that is a precursor to 3-GMP. The enzyme 23-cyclic-nucleotide 2-phosphodiesterase (E.C. 3.1.4.16) catalyses the hydrolysis of both 2,3-cyclic AMP and 2,3-cyclic GMP into 3-AMP and 3-GMP, respectively, at the 3-terminal of RNA. 2,3-cyclic phosphate termini are produced, as either intermediates or final products, during RNA cleavage by many different endoribonucleases. The enzyme RNA 3-phosphate cyclase also converts the 3-terminal phosphate in RNA into the 2,3-cyclic phosphodiester in the ATP-dependent reaction which involves formation of the covalent cyclase-AMP and the RNA-N3 pp5 A intermediates (PMID: 10397337). This enzyme could be involved in the maintenance of cyclic ends in tRNA splicing intermediates or in the cyclization of the 3 end of U6 snRNA (PMID: 9184239). Guanosine-2,3-cyclic phosphate is capable of blocking DNA synthesis in vitro (PMID: 7528887). 2, 3-cGMP seems to preferentially stimulate mature T-cells while 3, 5-cGMP preferentially acts on B-cells (PMID: 163786).

3-Keto-3-deoxy-AMP

C10H12N5O7P (345.0474332)

Capensinidin

C18H17O7+ (345.0974232)

An anthocyanidin cation consisting of benzopyrylium with hydroxy substituents at positions 3 and 7, a methoxy group at position 5 and a 4-hydroxy-3,5-dimethoxyphenyl group at position 2 respectively.

Hirsutidin

C18H17O7+ (345.0974232)

An anthocyanidin cation consisting of benzopyrylium with hydroxy substituents at positions 3 and 5, a methoxy group at position 7 and a 4-hydroxy-3,5-dimethoxyphenyl group at position 2.

Candimine

C18H19NO6 (345.1212314)

A natural product found in Hippeastrum morelianum and Hippeastrum candidum.

Isofenphos

2-[[Ethoxy[(1-methylethyl)amino]phosphinothioyl]oxy]benzoic acid 1-methylethyl ester

C15H24NO4PS (345.1163594)

Isofenphos is an Agricultural insecticide with contact and stomach actio C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

desulfosinalbin

Desulfo-p-hydroxybenzylglucosinolate

C14H19NO7S (345.0882184)

2-descarboxy-betanidin

C17H17N2O6+ (345.10865620000004)

Esomeprazole

5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl]-1H-1,3-benzodiazole

C17H19N3O3S (345.11470640000005)

A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor

Esomeprazole

5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole

C17H19N3O3S (345.11470640000005)

Esomeprazole is a proton pump inhibitor (brand names Nexium; Esomeprazole is a proton pump inhibitor which reduces gastric acid secretion through inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents formation of gastric acid.; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Esomeprazole is a proton pump inhibitor (brand names Nexium; Esomeprazole is a proton pump inhibitor (brand names Nexium; Lucen; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Lucen; A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [HMDB] Esomeprazole (brand names Nexium; Lucen; Esopral and Axagon in Italy) is a proton pump inhibitor which reduces gastric acid secretion through the inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents the formation of gastric acid. Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors

Molybdopterin precursor Z

2-amino-6-(2,5-dihydroxy-2-oxo-1,3,2lambda5-dioxaphosphinane-4-carbonyl)-4,6,7,8-tetrahydropteridin-4-one

C10H12N5O7P (345.0474332)

Molybdopterin precursor Z is a molybdopterin precursor. All molybdenum-containing oxotransferases use molybdenum in the form of a pterin-containing cofactor. In some of these enzymes, this cofactor consists of molybdenum ligated to a phosphorylated pterin, called molybdopterin (MPT). MPT is a tricyclic pyranopterin containing a cis-dithiolene group. Together, the metal and the pterin moiety form the redox reactive molybdenum cofactor (MoCo). Conversion of precursor Z to molybdopterin requires the opening of a cyclic phosphate to produce a terminal mono-ester and the transfer of sulfur to generate the dithiolene function essential for molybdenum ligation. Molybdopterin (MPT)-synthase is the enzyme necessary for the conversion of precursor Z into molybdopterin. The large and small subunits of molybdopterin synthase are both encoded from a single gene by overlapping open reading frames. Mutations in patients with deficiencies in MoCo biosynthesis usually occur in the enzymes catalyzing the first and second steps of biosynthesis, leading to the formation of precursor Z and MPT, respectively. The second step is catalyzed by the heterotetrameric MPT synthase protein consisting of two large (MoaE) and two small (MoaD) subunits with the MoaD subunits located at opposite ends of a central MoaE dimer. Previous studies have determined that the conversion of the sulfur- and metal-free precursor Z to MPT by MPT synthase involves the transfer of sulfur atoms from a C-terminal MoaD thiocarboxylate to the C-1 and C-2 positions of precursor Z. [HMDB] Molybdopterin precursor Z is a molybdopterin precursor. All molybdenum-containing oxotransferases use molybdenum in the form of a pterin-containing cofactor. In some of these enzymes, this cofactor consists of molybdenum ligated to a phosphorylated pterin, called molybdopterin (MPT). MPT is a tricyclic pyranopterin containing a cis-dithiolene group. Together, the metal and the pterin moiety form the redox reactive molybdenum cofactor (MoCo). Conversion of precursor Z to molybdopterin requires the opening of a cyclic phosphate to produce a terminal mono-ester and the transfer of sulfur to generate the dithiolene function essential for molybdenum ligation. Molybdopterin (MPT)-synthase is the enzyme necessary for the conversion of precursor Z into molybdopterin. The large and small subunits of molybdopterin synthase are both encoded from a single gene by overlapping open reading frames. Mutations in patients with deficiencies in MoCo biosynthesis usually occur in the enzymes catalyzing the first and second steps of biosynthesis, leading to the formation of precursor Z and MPT, respectively. The second step is catalyzed by the heterotetrameric MPT synthase protein consisting of two large (MoaE) and two small (MoaD) subunits with the MoaD subunits located at opposite ends of a central MoaE dimer. Previous studies have determined that the conversion of the sulfur- and metal-free precursor Z to MPT by MPT synthase involves the transfer of sulfur atoms from a C-terminal MoaD thiocarboxylate to the C-1 and C-2 positions of precursor Z.

3-(3-Amino-3-carboxypropyl)uridine

(2S)-2-amino-4-{3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl}butanoic acid

C13H19N3O8 (345.1172094)

1-(4-Chlorophenyl)-2-acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline

1-[1-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one

C19H20ClNO3 (345.1131640000001)

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

N-(3,4-dimethyl-1,2-oxazol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide

C17H19N3O3S (345.11470640000005)

D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003619 - Dansyl Compounds D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents BMS 182874 is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research[1].

Aquex

4-Chloro-N-(2,6-dimethylpiperidin-1-yl)-3-sulphamoylbenzene-1-carboximidic acid

C14H20ClN3O3S (345.09138400000006)

Cyclic apt

6-(6-aminopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol

C10H12N5O5PS (345.02967520000004)

D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

4-[2-(3,4-Dihydro-6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl]-3H-1,2,4-triazole-3,5(4H)-dione

4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)ethyl]-4,5-dihydro-3H-1,2,4-triazole-3,5-dione

C15H15N5O5 (345.10731400000003)

Oxo-ciprofloxacin

6-fluoro-4-oxo-1-(2-oxocyclopropyl)-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

C17H16FN3O4 (345.1124788)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

Oxociprofloxacin

1-Cyclopropyl-6-fluoro-7-(5-hydroxy-1,2,3,6-tetrahydropyrazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate

C17H16FN3O4 (345.1124788)

Triflumizole

N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethan-1-imine

C15H15ClF3N3O (345.0855686)

Vonoprazan

1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

C17H16FN3O2S (345.0947208)

Hirsutidin

3,5-Dihydroxy-2- (4-hydroxy-3,5-dimethoxyphenyl) -7-methoxy-1-benzopyrylium

C18H17O7 (345.0974232)

Capensinidin

3,7,4-Trihydroxy-5,3,5-trimethoxyflavylium

C18H17O7 (345.0974232)

MLS000849957

C18H19NO4S (345.10347340000004)

EP_M346

malbranpyrrole F

C19H20ClNO3 (345.1131640000001)

Izumiphenazine C

clopamide

C14H20ClN3O3S (345.09138400000006)

C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics

precursor Z

Molybdopterin precursor Z

C10H12N5O7P (345.0474332)

A linear-fused organic heterotetracyclic compound consisting of a [1,3,2]dioxaphosphinane fused to a pyran-4-one ring which is in turn fused to a pteridine ring system.

4-Pyridoxic acid O-hexoside

C14H19NO9 (345.10597640000003)

omeprazole

6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-methyl-1H-benzo[d]imidazole

C17H19N3O3S (345.11470640000005)

A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 8334 CONFIDENCE standard compound; INTERNAL_ID 1113 Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

GUANOSINE 3,5-CYCLIC MONOPHOSPHATE

"GUANOSINE 3,5-CYCLIC MONOPHOSPHATE"

C10H12N5O7P (345.0474332)

3,5-cyclic GMP

Guanosine-3,5-cyclic monophosphate

C10H12N5O7P (345.0474332)

A 3,5-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.

Thiamine monophosphate chloride dihydrate

[C12H18N4O4PS]+ (345.07863380000003)

Guanosine-3,5-cyclic monophosphate

C10H12N5O7P (345.0474332)

Guanosine cyclic monophosphate

C10H12N5O7P (345.0474332)

MMV676350

C17H16N3OClS (345.07025560000005)

Omeprazole-d3

C17H19N3O3S (345.11470640000005)

Cytosine arabinoside, (beta-D-Furanose-form, 5-Phosphate)

C9H13N3NaO8P (345.0337948)

Origin: Microbe, Pyrimidines

THMP

C12H18N4O4PS (345.07863380000003)

CGMP

C10H12N5O7P (345.0474332)

GUANOSINE, 5-CYCLIC MONOPHOSPHATE

C10H12N5O7P (345.0474332)

Omeprazole; AIF; CE0; CorrDec

C17H19N3O3S (345.11470640000005)

Omeprazole; AIF; CE10; CorrDec

C17H19N3O3S (345.11470640000005)

Omeprazole; AIF; CE30; CorrDec

C17H19N3O3S (345.11470640000005)

Omeprazole; AIF; CE0; MS2Dec

C17H19N3O3S (345.11470640000005)

Omeprazole; AIF; CE10; MS2Dec

C17H19N3O3S (345.11470640000005)

Omeprazole; AIF; CE30; MS2Dec

C17H19N3O3S (345.11470640000005)

Omeprazole; LC-tDDA; CE10

C17H19N3O3S (345.11470640000005)

Omeprazole; LC-tDDA; CE20

C17H19N3O3S (345.11470640000005)

Omeprazole; LC-tDDA; CE30

C17H19N3O3S (345.11470640000005)

Omeprazole; LC-tDDA; CE40

C17H19N3O3S (345.11470640000005)

Cyclic GMP

3,5-cyclic GMP

C10H12N5O7P (345.0474332)

COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Guanosine 3,5-cyclic monophosphate

C10H12N5O7P (345.0474332)

Thiamine monophosphate

R-Fluoxetine hydrochloride

(R)-Fluoxetine Hydrochloride

C17H19ClF3NO (345.110719)

C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

2-amino-4-(4-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

C20H15N3O3 (345.11133600000005)

Aristolochic acid

C16H9DNO8 (345.046917178)

3,8-Dinitro-6-phenyl-phenanthridine

C19H11N3O4 (345.0749526)

2-CHLORO-1-(6,7-DIMETHOXY-1-PHENYL-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHANONE

C19H20ClNO3 (345.1131640000001)

(S)-N1-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine.3HCl

C13H26Cl3N3O (345.11413560000005)

3-[2-(1H-benzimidazol-2-ylsulfinylmethyl)-3-methylpyridin-4-yl]oxypropan-1-ol

C17H19N3O3S (345.11470640000005)

4-BENZYLPIPERIDINE-1-CARBOXIMIDAMIDE HYDROIODIDE

C13H20IN3 (345.070191)

(R)-METHYL 5-AMINO-3-(1-(2-(TRIFLUOROMETHYL)PHENYL)ETHOXY)THIOPHENE-2-CARBOXYLATE

C15H14F3NO3S (345.06464500000004)

Bilanafos-sodium

C11H21N3NaO6P (345.1065616)

N-(4-(5-(FURAN-2-YL)-1,3,4-OXADIAZOL-2-YL)PHENYL)-2-PHENYLACETAMIDE

C20H15N3O3 (345.11133600000005)

1-hydroxy-4-[(4-methoxyphenyl)amino]anthraquinone

C21H15NO4 (345.10010300000005)

3,3-Diphenyltetrahydrofuran-2-ylidene(dimethyl)ammonium bromide

C18H20BrNO (345.07281700000004)

(Z)-3-(4-BROMOPHENYL)-N,N-DIMETHYL-3-(3-PYRIDYL)ALLYLAMINEDIHYDROCHLORIDE

C15H14Cl2FNO3 (345.0334726)

Fmoc-beta-chloro-L-alanine

C18H16ClNO4 (345.07678060000006)

2-CHLORO-3-FORMYL-4-IODOPYRIDINE

C18H19NO4S (345.10347340000004)

3-(3-BROMOPHENYL)-N,N,N-TRIETHYL-3-OXOPROP-1-EN-1-AMINIUM CHLORIDE

C15H21BrClNO (345.04949460000006)

3-(4-CHLORO-BENZENESULFONYL)-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

C15H20ClNO4S (345.08015100000006)

1-nitrocoronene

C24H11NO2 (345.0789746)

9H-Fluoren-9-ylmethyl (2-bromoethyl)carbamate

C17H16BrNO2 (345.0364336)

(s)-(+)-n-(3,5-dinitrobenzoyl)-alpha-phenylglycine

C15H11N3O7 (345.0596976)

2,3,4,5-Tetrahydro-7,8-dinitro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine

C13H10F3N3O5 (345.0572526)

1-(TERT-BUTOXYCARBONYL)-5-(TRIFLUOROMETHOXY)INDOLE-2-BORONIC ACID

C14H15BF3NO5 (345.09953260000003)

[1-[(2-methylpropan-2-yl)oxycarbonyl]-6-(trifluoromethoxy)indol-2-yl]boronic acid

C14H15BF3NO5 (345.09953260000003)

Methyl a-[[2-(thien-2-yl)ethyl]amino]-alpha-(2-chlorophenyl)acetate hydrochloride

C15H17Cl2NO2S (345.03570020000006)

8-(4-Bromobenzyl)-2,4-dimethyl-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one

C16H16BrN3O (345.0476666)

Fluoxetine Hydrochloride

C17H19ClF3NO (345.110719)

D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065690 - Cytochrome P-450 CYP2D6 Inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators

((2-BROMO-6-NITROBENZYL)OXY)(TERT-BUTYL)DIMETHYLSILANE

C13H20BrNO3Si- (345.03957500000007)

4-Methoxy-2-naphthylamine p-toluenesulfonate salt

C18H19NO4S (345.10347340000004)

(2-AMINO-PHENYL)-PYRROLIDIN-1-YL-METHANONE

C14H20BrNO2S (345.03980400000006)

4-methylsulfanyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one

C20H15N3OS (345.09357800000004)

tert-butyl 5-(trifluoromethylsulfonyloxy)-2,3,4,7-tetrahydroazepine-1-carboxylate

C12H18F3NO5S (345.0857734)

2,4,5,6-Tetrahydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazole benzenesulfonate

C12H15N3O5S2 (345.04531)

ETHYL 4-((3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)BENZOATE

C15H11ClF3NO3 (345.03795220000006)

Tris(2-carboxyethyl) isocyanurate

C12H15N3O9 (345.080826)

4-PHENYL-1-(PHENYLSULFONYL)PIPERIDINE-4-CARBOXYLIC ACID

C18H19NO4S (345.10347340000004)

benzene-1,2,4-tricarboxylic acid,3-(2-methylimidazol-1-yl)propanenitrile

C16H15N3O6 (345.096081)

Vonoprazan Impurity 2

C17H16FN3O2S (345.0947208)

2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid

C15H17Cl2NO4 (345.0534582000001)

2-amino-4-(3-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

C20H15N3O3 (345.11133600000005)

Benzyl [1-(4-bromophenyl)cyclopropyl]carbamate

C17H16BrNO2 (345.0364336)

5-methoxy-1-(4-methoxyphenyl)sulfonylindole-3-carbaldehyde

C17H15NO5S (345.06709)

(2R)-Amino(3,5-dinitrophenyl)acetic acid

C15H11N3O7 (345.0596976)

3,4-bis(2,4,5-trimethylthiophen-3-yl)pyrrole-2,5-dione

C18H19NO2S2 (345.08571539999997)

Sp-Camps

C10H12N5O5PS (345.02967520000004)

D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid

C20H15N3O3 (345.11133600000005)

alpha-Methylene adenosine monophosphate

C11H16N5O6P (345.08381660000003)

3-O-phosphonatoadenosine

C10H12N5O7P-2 (345.0474332)

COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

(+)-(S)-Fluoxetine Hydrochloride

C17H19ClF3NO (345.110719)

Ethyl 5-amino-3-(4-methoxyphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylate

C16H15N3O4S (345.078323)

(E)-3-(4-fluorophenyl)-N-[(pyrazine-2-carbonylamino)carbamothioyl]prop-2-enamide

C15H12FN5O2S (345.06957040000003)

4-amino-N-[3-(3H-1,3-benzoxazol-2-ylidene)-4-oxo-1-cyclohexa-1,5-dienyl]benzamide

C20H15N3O3 (345.11133600000005)

methyl 2-[4-(4-chlorobenzoyl)-3,4-dihydro-2H-1,4-benzoxazin-3-yl]acetate

C18H16ClNO4 (345.07678060000006)

2-[[3-(5-Methyl-2-furanyl)-1-oxopropyl]amino]benzene-1,4-dicarboxylic acid dimethyl ester

C18H19NO6 (345.1212314)

N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-[[1-(phenylmethyl)-2-imidazolyl]thio]acetamide

C15H15N5OS2 (345.071798)

2-[[4-(4-Methoxyphenyl)-2-pyrimidinyl]thio]-1-(4-morpholinyl)ethanone

C17H19N3O3S (345.11470640000005)

N6-Methyl-deoxy-adenosine-5-monophosphate

C11H16N5O6P (345.08381660000003)

Formamide, N-((4-((3-(trifluoromethyl)phenyl)amino)-3-pyridinyl)sulfonyl)-

C13H10F3N3O3S (345.0394946)

Omeprazole D3

C17H19N3O3S (345.11470640000005)

2-(2,4-Dichlorophenoxy)-5-(pyridin-2-ylmethyl)phenol

C18H13Cl2NO2 (345.0323298)

N-[[3-Fluoro-4-ethoxy-pyrid-2-YL]ethyl]-N-[5-nitrilomethyl-pyridyl]-thiourea

C16H16FN5OS (345.1059538)

2-Chloro-N-[(3r)-2-Oxo-1,2,3,4-Tetrahydroquinolin-3-Yl]-6h-Thieno[2,3-B]pyrrole-5-Carboxamide

C16H12ClN3O2S (345.0338722)

N-Hydroxy 1N(4-methoxyphenyl)sulfonyl-4-(Z,E-N-methoxyimino)pyrrolidine-2R-carboxamide

C13H19N3O6S (345.0994514)

D-Para-Chlorophenyl-1-Acteamidoboronic Acid Alanine

C13H19BClN2O6- (345.10246340000003)

[(1R)-1-acetamido-2-(4-chlorophenyl)ethyl]-[(2S)-2-amino-3-hydroxy-3-oxo-propoxy]-dihydroxy-boron

C13H19BClN2O6- (345.10246340000003)

Chromophore (glu-tyr-gly)

C16H15N3O6 (345.096081)

Vonoprazan

C17H16FN3O2S (345.0947208)

2-[(2-Acetyl-5-tert-butylthiophen-3-yl)carbamoyl]benzoic acid

C18H19NO4S (345.10347340000004)

4-(4-chlorophenyl)-N-[2-(5-methyl-1H-imidazol-2-yl)ethyl]thiophene-2-carboxamide

C17H16ClN3OS (345.0702556)

2-[3-(7-bromo-9H-pyrido[3,4-b]indol-1-yl)propyl]guanidine

C15H16BrN5 (345.0588996)

8-amino-2-hydroxy-4a,5a,9,11,11a,12a-hexahydro[1,3,2]dioxaphosphinino[4,5:5,6]pyrano[3,2-g]pteridine-10,12(4H,6H)-dione 2-oxide

C10H12N5O7P (345.0474332)

1-{[(2R,3S)-3-(2-chlorophenyl)-2-(4-fluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-3-ol

C17H13ClFN3O2 (345.068028)

[6-Amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium

C21H17N2O3+ (345.12391119999995)

D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D012235 - Rhodamines D004396 - Coloring Agents > D005456 - Fluorescent Dyes

Adenosine-5-monophosphate(2-)

C10H12N5O7P-2 (345.0474332)

Syringetin(1-)

C17H13O8- (345.0610398)

The 3-oxoanion of syringetin.

dGMP dianion

C10H12N5O7P-2 (345.0474332)

Adenosine 2-phosphate(2-)

C10H12N5O7P-2 (345.0474332)

Adenosine 5-phosphoramidate(1-)

Ser-Cys-His

C12H19N5O5S (345.1106844)

8,5-Cyclo-2-deoxyguanosine monophosphate

C10H12N5O7P (345.0474332)

An organic heterotetracyclic compound obtained by intramolecular formation of a C-C bond between positions 8 and 5 of dGMP.

ddhGMP

C10H12N5O7P (345.0474332)

2-(1-Iminoethyl)-4-[[5-(3-methylanilino)-1,3,4-thiadiazol-2-yl]thio]-3-oxobutanenitrile

C15H15N5OS2 (345.071798)

[4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-2-methoxyphenyl] furan-2-carboxylate

C16H11NO6S (345.03070660000003)

methyl 5-(4-hydroxyphenyl)-7-methyl-4-oxo-2-sulfanylidene-5,6-dihydro-1H-pyrido[2,3-d]pyrimidine-6-carboxylate

C16H15N3O4S (345.078323)

(5E)-2-phenylimino-5-[(1-phenylpyrrol-2-yl)methylidene]-1,3-thiazolidin-4-one

C20H15N3OS (345.09357800000004)

5-Amino-11,14-dihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4,11-trien-7-one

C10H12N5O7P (345.0474332)

Azinphos-ethyl

C12H16N3O3PS2 (345.0370676)

C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor

2,3-Cyclic GMP

C10H12N5O7P (345.0474332)

A 2,3-cyclic purine nucleotide in which guanosine is used as the parent nucleoside.

p-Hydroxybenzyldesulphoglucosinolate

C14H19NO7S (345.0882184)

3-AMP(2-)

C10H12N5O7P (345.0474332)

The organophosphate oxoanion which results from the removal of two protons from the phosphate group of 3-AMP; major species at pH 7.3.

2-deoxyguanosine 5-monophosphate(2-)

C10H12N5O7P (345.0474332)

A 2-deoxyribonucleoside 5-monophosphate(2-) obtained by deprotonation of the phosphate OH groups of 2-deoxyguanosine 5-monophosphate (dGMP).

8-oxo-dAMP(2-)

C10H12N5O7P (345.0474332)

An organophosphate oxoanion obtained by deprotonation of the diphosphate OH groups of 8-oxo-dAMP.

UNII:0514MAW53A

C15H24NO4PS (345.1163594)

C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

Aquex

C14H20ClN3O3S (345.09138400000006)

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

C17H19N3O3S (345.11470640000005)

3-(3-Amino-3-carboxypropyl)uridine

C13H19N3O8 (345.1172094)

2-amino-9-(2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl)-3H-purin-6-one

C10H12N5O7P (345.0474332)

SPF-32629B

C18H19NO6 (345.1212314)

A carboxylic ester obtained by the formal condensation of the benzylic hydroxy group of 4-hydroxy-6-[hydroxy(phenyl)methyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid with 3-methylbutanoic acid. It is isolated from the culture broth of Penicillium sp. SPF-32629 and acts as an inhibitor of the enzyme chymase (EC 3.4.21.39).

Adenosine 2-phosphate(2-)

C10H12N5O7P (345.0474332)

An organophosphate oxoanion obtained by removal of two protons from the phosphate group of adenosine 2-phosphate; major species at pH 7.3.

thiamine(1+) monophosphate

C12H18N4O4PS (345.07863380000003)

A thiamine phosphate that is thiamin(1+) in which the hydroxy group is replaced by a phosphate group.

adenosine 5-monophosphate(2-)

C10H12N5O7P (345.0474332)

A nucleoside 5-monophosphate(2-) that results from the removal of two protons from the phosphate group of adenosine 5-monophosphate (AMP).

2',3' cyclic GMP

C10H12N5O7P (345.0474332)

3',5' cyclic GMP

C10H12N5O7P (345.0474332)

Aminocarboxypropyluridine

C13H19N3O8 (345.1172094)

Guanosine 3'5-cyclic monophosphate

C10H12N5O7P (345.0474332)

cGMP. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=7665-99-8 (retrieved 2024-07-02) (CAS RN: 7665-99-8). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

CGP 25454A

C15H21Cl2N3O2 (345.1010746)

CGP 25454A is a selective presynaptic dopamine autoreceptor antagonist which induces the increase of dopamine and acetyl choline. CGP 25454A can be used for major depression research[1].

PF-06685249

C17H16ClN3O3 (345.08801359999995)

PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC50 of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 can be used for diabetic nephropathy research[1].

VU10010

C17H16ClN3OS (345.0702556)

VU10010 is a potent, highly selective and allosteric M4 mAChR potentiator with an EC50 of 400 nM. VU10010 binds to an allosteric site on M4 mAChR and increases affinity for acetylcholine and coupling to G proteins. VU10010 increases carbachol-induced depression of transmission at excitatory but not inhibitory synapses in the hippocampus[1].

Zacopride (hydrochloride)

C15H21Cl2N3O2 (345.1010746)

Zacopride hydrochloride is a highly potent 5-HT3 receptor antagonist with Kis of 0.38 and 373 nM for 5-HT3 and 5-HT4 receptor, respectively. Zacopride hydrochloride is also a moderate IK1 channel agonist. Zacopride hydrochloride exerts significant antiarrhythmic and cardiac protective effects[1][2][3].